

Jayesh M Bhatt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7221003/publications.pdf>

Version: 2024-02-01

73
papers

989
citations

567144

15
h-index

501076

28
g-index

78
all docs

78
docs citations

78
times ranked

1506
citing authors

#	ARTICLE	IF	CITATIONS
1	Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2012, 11, 288-292.	0.3	113
2	ERS statement on tracheomalacia and bronchomalacia in children. <i>European Respiratory Journal</i> , 2019, 54, 1900382.	3.1	113
3	Treatment of pulmonary exacerbations in cystic fibrosis. <i>European Respiratory Review</i> , 2013, 22, 205-216.	3.0	108
4	ERS statement on the multidisciplinary respiratory management of ataxia telangiectasia. <i>European Respiratory Review</i> , 2015, 24, 565-581.	3.0	56
5	Impact of the A (H1N1) pandemic influenza (season 2009â€“2010) on patients with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2011, 10, 370-376.	0.3	53
6	Eradication therapy for <i>Burkholderia cepacia</i> complex in people with cystic fibrosis. <i>The Cochrane Library</i> , 2016, 11, CD009876.	1.5	37
7	Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. <i>The Cochrane Library</i> , 2017, 3, CD002009.	1.5	34
8	An update on controversies in e-cigarettes. <i>Paediatric Respiratory Reviews</i> , 2020, 36, 75-86.	1.2	34
9	Eradication therapy for <i>Burkholderia cepacia</i> complex in people with cystic fibrosis. <i>The Cochrane Library</i> , 2019, 2019, CD009876.	1.5	31
10	Life-threatening hypersensitivity pneumonitis secondary to e-cigarettes. <i>Archives of Disease in Childhood</i> , 2020, 105, 1114-1116.	1.0	31
11	Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. , 2006, , CD002009.		29
12	The Management of Pre-School Wheeze. <i>Paediatric Respiratory Reviews</i> , 2011, 12, 70-77.	1.2	27
13	An improved urine collection pad method: a randomised clinical trial. <i>Archives of Disease in Childhood</i> , 2004, 89, 773-775.	1.0	26
14	Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. , 2012, , CD002009.		19
15	Ataxia telangiectasia: presentation and diagnostic delay. <i>Archives of Disease in Childhood</i> , 2017, 102, 328-330.	1.0	19
16	Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. , 2010, , CD002009.		17
17	Treatment massive haemoptysis in cystic fibrosis with tranexamic acid. <i>Journal of the Royal Society of Medicine</i> , 2011, 104, 49-52.	1.1	17
18	Bronchopulmonary Dysplasia Within and Beyond the Neonatal Unit. <i>Advances in Neonatal Care</i> , 2016, 16, 17-25.	0.5	17

#	ARTICLE	IF	CITATIONS
19	Do environmental pollutants influence the onset of respiratory syncytial virus epidemics or disease severity?. Paediatric Respiratory Reviews, 2004, 5, 333-338.	1.2	15
20	Microbiological surveillance in lung disease in ataxia telangiectasia. European Respiratory Journal, 2014, 43, 1797-1801.	3.1	15
21	Eradication therapy forBurkholderia cepaciacomplex in people with cystic fibrosis. , 2014, , CD009876.		15
22	Growth and nutrition in children with ataxia telangiectasia. Archives of Disease in Childhood, 2016, 101, 1137-1141.	1.0	15
23	E cigarettes: Tar Wars: The (Tobacco) Empire Strikes Back. Archives of Disease in Childhood, 2019, 104, 1027-1039.	1.0	14
24	Intra-Subject Variability in Lung Dose in Healthy Volunteers Using Five Conventional Portable Inhalers. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2004, 17, 231-238.	1.2	13
25	Weaning oxygen in infants with bronchopulmonary dysplasia. Paediatric Respiratory Reviews, 2021, 39, 82-89.	1.2	12
26	Tracheomalacia and bronchomalacia in children: response to the ERS statement. European Respiratory Journal, 2019, 54, 1902271.	3.1	9
27	Paediatric pulmonary Langerhans cell histiocytosis. Breathe, 2020, 16, 200003.	0.6	9
28	Management of severe pulmonary Langerhans cell histiocytosis in children. Pediatric Pulmonology, 2020, 55, 2074-2081.	1.0	9
29	Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. , 2014, , CD002009.		8
30	Preschool Wheeze is Not Asthma: A Clinical Dilemma. Indian Journal of Pediatrics, 2014, 81, 1193-1195.	0.3	8
31	Ataxia telangiectasia: why should the ERS care?. European Respiratory Journal, 2015, 46, 1557-1560.	3.1	6
32	Impact of a protocol-driven unified service for neonates with bronchopulmonary dysplasia. ERJ Open Research, 2019, 5, 00183-2018.	1.1	6
33	A public health emergency among young people. Lancet Respiratory Medicine,the, 2020, 8, 231-233.	5.2	6
34	NICE guidelines on bronchiolitis: a robust appraisal of current evidence. British Journal of Hospital Medicine (London, England: 2005), 2016, 77, 212-215.	0.2	5
35	Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. The Cochrane Library, 2019, 2019, CD002009.	1.5	5
36	Monogenic diabetes mellitus in cystic fibrosis. Archives of Disease in Childhood, 2019, 104, 887-889.	1.0	5

#	ARTICLE	IF	CITATIONS
37	Recognition and management of children with protracted bacterial bronchitis. British Journal of Hospital Medicine (London, England: 2005), 2015, 76, 398-404.	0.2	4
38	Fifteen-minute consultation: An evidence-based approach to the child with preschool wheeze. Archives of Disease in Childhood: Education and Practice Edition, 2018, 103, 7-14.	0.3	4
39	Extracorporeal Life Support for Respiratory Failure in Patients With Electronic Cigarette or Vaping Product Use—Associated Lung Injury. Critical Care Medicine, 2021, Publish Ahead of Print, .	0.4	3
40	Pneumomediastinum as a presenting feature of allergic bronchopulmonary aspergillosis in a child with cystic fibrosis. Journal of the Royal Society of Medicine, 2012, 105, 36-39.	1.1	2
41	The ERS approach to e-cigarettes is entirely rational. European Respiratory Journal, 2020, 55, 2000413.	3.1	2
42	Fructose 1,6-bisphosphatase deficiency as a cause of childhood interstitial lung disease. Pediatric Pulmonology, 2021, 56, 2362-2365.	1.0	2
43	Structured approach to monitoring and weaning off home oxygen therapy in neonatal respiratory disease. , 2021, , 133-146.		2
44	Quality and cost improvement in neonatal prescribing through clinical audit. Clinical Governance, 2004, 9, 232-236.	0.4	1
45	Myths and maxims in paediatric respiratory medicine. Breathe, 2018, 14, 5-7.	0.6	1
46	Update of the European paediatric respiratory medicine syllabus. Breathe, 2019, 15, 173-180.	0.6	1
47	Clues beyond the lung: an unusual diagnosis in an infant with chronic lung disease. Breathe, 2020, 16, 190319.	0.6	1
48	The role of the pediatrician in caring for children with tracheobronchomalacia. Expert Review of Respiratory Medicine, 2020, 14, 679-689.	1.0	1
49	Epidemiology, genetics, pathophysiology and prognosis of CF. , 2021, , 435-445.		1
50	Diuretic use and duration of home oxygen therapy in infants with Bronchopulmonary Dysplasia (BPD). , 2019, , .		1
51	Why is a paediatric respiratory specialist integral to the paediatric rheumatology clinic?. Breathe, 2020, 16, 200212.	0.6	1
52	E-cigarette company tactics in sports advertising. Lancet Respiratory Medicine, the, 2022, 10, 634-636.	5.2	1
53	A clinical approach to a wheezy infant. Paediatrics and Child Health (United Kingdom), 2012, 22, 307-309.	0.2	0
54	Safety, Efficacy, and Patient Acceptability of Montelukast in Exercise-Induced Asthma. Clinical Medicine Insights Therapeutics, 2012, 4, CMT.S7389.	0.4	0

#	ARTICLE	IF	CITATIONS
55	Preschool Wheeze is Not Asthma: A Clinical Dilemma – Authors' Reply. Indian Journal of Pediatrics, 2015, 82, 971-972.	0.3	0
56	Where Are We Now with the Role of Steroids in the Management of Bronchopulmonary Dysplasia in Extremely Premature Babies?. Frontiers in Pediatrics, 2016, 4, 85.	0.9	0
57	P81 – What is the ideal target preterm population that might benefit from the expensive palivizumab prophylaxis?. , 2017, , .		0
58	P82 – Comparison of rsv hospitalisation in preterm infants with chronic lung disease who do not qualify for palivizumab prophylaxis with those who qualify in nottingham, uk. , 2017, , .		0
59	Preschool wheeze. InnovAiT, 2017, 10, 756-757.	0.0	0
60	It's not all about inhaled treatment: challenges with oral therapy in paediatric respiratory medicine. Breathe, 2021, 17, 210005.	0.6	0
61	Presentation and diagnostic delay in ataxia telangiectasia (A-T). , 2015, , .		0
62	Too sweet for too long?. Endocrine Abstracts, 0, , .	0.0	0
63	Sniff nasal inspiratory pressure and peak cough flow in children with ataxia telangiectasia. , 2016, , .		0
64	Weight-based oxygen flow rate is predictive of successful weaning of long-term oxygen therapy in babies with bronchopulmonary dysplasia. , 2016, , .		0
65	Maternal smoking in pregnancy increases the duration of home oxygen therapy in infants with bronchopulmonary dysplasia. , 2017, , .		0
66	Caucasian small for gestational age infants with bronchopulmonary dysplasia require longer, and more intensive treatment for their disease than appropriate for gestational age, and non-Caucasian counterparts.. , 2018, , .		0
67	Early experience of oxygen enhanced magnetic resonance imaging (OE-MRI) in ataxia telangiectasia (A-T). , 2018, , .		0
68	A practical, evidence-based approach to postneonatal management of children with bronchopulmonary dysplasia. Pediatric Respiratory and Critical Care Medicine, 2019, 3, 42.	0.4	0
69	Target Oximetry in babies with Bronchopulmonary Dysplasia at Cessation of Oxygen Therapy. , 2019, , .		0
70	Prediction & management of respiratory co-morbidities following congenital tracheoesophageal fistula repair: a multidisciplinary approach. , 2019, , .		0
71	Is aspergillus isolation (without ABPA) associated with a decline in FEV1 in CF?. , 2019, , .		0
72	Does declining nutritional status in ataxia telangiectasia cause decline in immunological function. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
73	Duration of home oxygen therapy and postnatal catch-up growth in bronchopulmonary dysplasia. , 2020, , .		0